FiercePharma

Particle Sciences Develops Proprietary Nasal Delivery Formulation Used in Neurelis' Recently Announced Successful Phase I Pharma

BETHLEHEM, Pa., June 22, 2011 /PRNewswire/ -- In a recent announcement by Neurelis, a proprietary intranasal formulation of diazepam (NRL-1) achieved positive clinical results in a Phase I ...
Fierce Healthcare

Robert W. Lee, Ph.D. Joins Particle Sciences as Vice President of Pharmaceutical Development

BETHLEHEM, Pa., April 28 /PRNewswire/ -- Particle Sciences, Inc. today announced the appointment of Robert W. Lee, Ph.D. to the position of Vice President, Pharmaceutical Development. Dr. Lee joins ...
EDN

Particle Sciences Expands Its DOSE™ Program With Additional Proprietary Modeling Capabilities

BETHLEHEM, Pa., Jan. 3, 2012 /PRNewswire/ — Particle Sciences, a leading drug delivery CRO, has added a third computational module to its DOSE™ program. The DOSE™ program uses a combination of ...
FiercePharma

Particle Sciences and Actavis Enter into Joint Development Agreement

BETHLEHEM, Pa., April 1, 2014 /PRNewswire/ -- Particle Sciences, a drug delivery Contract Development and Manufacturing Organization (CDMO), today announced that they have entered into an exclusive ...